{
  "pmid": "29706503",
  "uid": "29706503",
  "title": "Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy.",
  "abstract": "INTRODUCTION: Optimal end points in phase 2 trials evaluating salvage therapy for metastatic urothelial carcinoma are necessary to identify promising drugs, particularly immunotherapeutics, where response and progression-free survival may be unreliable. We developed a nomogram using data from phase 2 trials of historical agents to estimate the 12-month overall survival (OS) for patients to which observed survival of nonrandomized data sets receiving immunotherapies could be compared. PATIENTS AND METHODS: Survival and data for major prognostic factors were obtained from phase 2 trials: hemoglobin, performance status, liver metastasis, treatment-free interval, and albumin. A nomogram was developed to estimate 12-month OS. Patients were randomly allotted to discovery:validation data sets in a 2:1 ratio. Calibration plots were constructed in the validation data set and data bootstrapped to assess performance. The nomogram was tested on external nonrandomized cohorts of patients receiving pemetrexed and atezolizumab. RESULTS: Data were available from 340 patients receiving sunitinib, everolimus, docetaxel + vandetanib, docetaxel + placebo, pazopanib, paclitaxel, or docetaxel. Calibration and prognostic ability were acceptable (c index = 0.634; 95% confidence interval [CI], 0.596-0.652). Observed 12-month survival for patients receiving pemetrexed (n = 127, 23.5%; 95% CI, 16.2-31.7) was similar to nomogram-predicted survival (19%; 95% CI, 16.5-21.5; P > .05), while observed results with atezolizumab (n = 403, 39.0%; 95% CI, 34.1-43.9) exceeded predicted results (24.6%; 95% CI, 23.4-25.8; P < .001). CONCLUSION: This nomogram may be a useful tool to interpret results of nonrandomized phase 2 trials of salvage therapy for metastatic urothelial carcinoma by assessing the OS contributions of drug intervention independent of prognostic variables.",
  "authors": [
    {
      "last_name": "Sonpavde",
      "fore_name": "Guru",
      "initials": "G",
      "name": "Guru Sonpavde",
      "affiliations": [
        "University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL. Electronic address: gurup_sonpavde@dfci.harvard.edu."
      ]
    },
    {
      "last_name": "Pond",
      "fore_name": "Gregory Russell",
      "initials": "GR",
      "name": "Gregory Russell Pond",
      "affiliations": [
        "Ontario Clinical Oncology Group, Hamilton, ON."
      ]
    },
    {
      "last_name": "Rosenberg",
      "fore_name": "Jonathan E",
      "initials": "JE",
      "name": "Jonathan E Rosenberg",
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, NY."
      ]
    },
    {
      "last_name": "Choueiri",
      "fore_name": "Toni K",
      "initials": "TK",
      "name": "Toni K Choueiri",
      "affiliations": [
        "Dana-Farber Cancer Institute, Boston, MA."
      ]
    },
    {
      "last_name": "Bellmunt",
      "fore_name": "Joaquim",
      "initials": "J",
      "name": "Joaquim Bellmunt",
      "affiliations": [
        "Dana-Farber Cancer Institute, Boston, MA."
      ]
    },
    {
      "last_name": "Regazzi",
      "fore_name": "Ashley Marie",
      "initials": "AM",
      "name": "Ashley Marie Regazzi",
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, NY."
      ]
    },
    {
      "last_name": "Mullane",
      "fore_name": "Stephanie A",
      "initials": "SA",
      "name": "Stephanie A Mullane",
      "affiliations": [
        "Dana-Farber Cancer Institute, Boston, MA."
      ]
    },
    {
      "last_name": "Necchi",
      "fore_name": "Andrea",
      "initials": "A",
      "name": "Andrea Necchi",
      "affiliations": [
        "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy."
      ]
    },
    {
      "last_name": "Raggi",
      "fore_name": "Daniele",
      "initials": "D",
      "name": "Daniele Raggi",
      "affiliations": [
        "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy."
      ]
    },
    {
      "last_name": "Lee",
      "fore_name": "Jae-Lyun",
      "initials": "JL",
      "name": "Jae-Lyun Lee",
      "affiliations": [
        "Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea."
      ]
    },
    {
      "last_name": "Lee",
      "fore_name": "Soonil",
      "initials": "S",
      "name": "Soonil Lee",
      "affiliations": [
        "Dankook University Hospital, Dankook University College of Medicine, Cheonan, South Korea."
      ]
    },
    {
      "last_name": "Simpson",
      "fore_name": "Joe",
      "initials": "J",
      "name": "Joe Simpson",
      "affiliations": [
        "Genentech Inc, South San Francisco, CA."
      ]
    },
    {
      "last_name": "Derleth",
      "fore_name": "Christina Louise",
      "initials": "CL",
      "name": "Christina Louise Derleth",
      "affiliations": [
        "Genentech Inc, South San Francisco, CA."
      ]
    },
    {
      "last_name": "Lin",
      "fore_name": "Shih-Wen",
      "initials": "SW",
      "name": "Shih-Wen Lin",
      "affiliations": [
        "Genentech Inc, South San Francisco, CA."
      ]
    },
    {
      "last_name": "Bajorin",
      "fore_name": "Dean F",
      "initials": "DF",
      "name": "Dean F Bajorin",
      "affiliations": [
        "Memorial Sloan Kettering Cancer Center, New York, NY."
      ]
    }
  ],
  "journal": {
    "title": "Clinical genitourinary cancer",
    "iso_abbreviation": "Clin Genitourin Cancer",
    "issn": "1938-0682",
    "issn_type": "Electronic",
    "volume": "16",
    "issue": "4",
    "pub_year": "2018",
    "pub_month": "Aug"
  },
  "start_page": "e961",
  "end_page": "e967",
  "pages": "e961-e967",
  "language": "eng",
  "publication_types": [
    "Clinical Trial, Phase II",
    "Journal Article"
  ],
  "keywords": [
    "Aged",
    "Antibodies, Monoclonal",
    "Antibodies, Monoclonal, Humanized",
    "Carcinoma, Transitional Cell",
    "Disease-Free Survival",
    "Female",
    "Humans",
    "Immunotherapy",
    "Male",
    "Middle Aged",
    "Nomograms",
    "Pemetrexed",
    "Prognosis",
    "Prospective Studies",
    "Random Allocation",
    "Salvage Therapy",
    "Treatment Outcome",
    "Urinary Bladder Neoplasms"
  ],
  "article_ids": {
    "pubmed": "29706503",
    "mid": "NIHMS1044512",
    "pmc": "PMC6697267",
    "doi": "10.1016/j.clgc.2018.03.016",
    "pii": "S1558-7673(18)30089-2"
  },
  "doi": "10.1016/j.clgc.2018.03.016",
  "pmc_id": "PMC6697267",
  "dates": {
    "completed": "2019-02-04",
    "revised": "2022-04-08"
  },
  "chemicals": [
    "Antibodies, Monoclonal",
    "Antibodies, Monoclonal, Humanized",
    "Pemetrexed",
    "atezolizumab"
  ],
  "grants": [
    {
      "grant_id": "P30 CA008748",
      "agency": "NCI NIH HHS",
      "country": "United States"
    }
  ],
  "search_metadata": {
    "search_type": "all_publications",
    "retrieved_date": "2025-07-30T14:52:44.932146",
    "pmid": "29706503"
  }
}